However, emerging clinical evidence indicates that after prolonged AR signaling inhibition, ~15–25% of patients with advanced PCa develop tumors characterized by AR independence, neuroendocrine phenotype, and stemness features [8,9,10,11]. The gene discussed is AR; the disease is posterior cortical atrophy.